BIO Urges Clinton, Congress to Drop Drug Reimportation Section of Ag Appropriations Bill
- Contact: Dan Eramian
Carrie Housman
(202) 962-9200
WASHINGTON, D.C. (October 18, 2000) - Biotechnology Industry Organization (BIO) President, Carl B. Feldbaum, today issued the following statement on the drug reimportation bill:
President Clinton should send the ag appropriations bill back to Congress with instructions to delete the drug reimportation section.
Congress focused on a stop-gap, election year 'solution' to the prescription drug issue. But the reimportation approach will harm the FDA and could put the health of seniors at risk.
This is electoral politics at its worst. I predict this scheme will not be implemented primarily because it puts public health at risk.
BIO represents more than 900 biotech companies, academic institutions and state biotech centers in all 50 U.S. states and in 26 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.
###
About BIO
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling “innovations transforming our world.” Subscribe to BIOtechNOW.
